20 Fewer Breathing Interruptions per Hour With Tirzepatide
SURMOUNT-OSA studied tirzepatide in adults who had both obesity and moderate-to-severe obstructive sleep apnea. Its primary endpoint was the apnea–hypopnea index, which measures breathing interruptions per hour of sleep. The findings are specific to that clinical population and trial design, not a replacement for sleep-apnea evaluation or personal treatment planning.
AHI changed by −25.3 versus −5.3 events per hour in the trial without PAP at baseline, a −20.0-event-per-hour difference; the corresponding difference in the PAP trial was −23.8 events per hour.
Both primary comparisons were statistically significant. The trials also reported improvement across prespecified secondary measures, while gastrointestinal events were the most frequently reported adverse events and were mostly mild to moderate.
Turn the study result into a better program comparison
If this study prompts you to explore GLP-1 care, separate the evidence result from the program decisions it cannot make. Compare providers on available plans, clinician access, medication status, public price terms, follow-up, and enrollment conditions. The reviewed brands below have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- Adults with moderate-to-severe obstructive sleep apnea and obesity; one trial enrolled people not using PAP and one enrolled people using PAP
- Follow-up
- 52 weeks
- Treatment comparison
- Maximum tolerated once-weekly tirzepatide dose of 10 mg or 15 mg compared with placebo for 52 weeks
- Study design
- Two phase 3, double-blind, randomized, placebo-controlled trials
A study result is not a personal treatment plan
This study did not replace sleep-apnea assessment, PAP decisions, or care from a sleep specialist. It does not decide whether tirzepatide is appropriate for an individual, what a provider can prescribe, or whether insurance will cover treatment. Those questions require a licensed clinician and a review of current plan terms.
Compare GLP-1 programsWhat this result does not show
- The results apply to adults with both moderate-to-severe obstructive sleep apnea and obesity, not to every person interested in weight management.
- The two trials enrolled different groups according to baseline PAP use, so their results should retain that context.
- The study does not compare telehealth providers, program affordability, coverage, pharmacy access, or individual treatment outcomes.
- The study was funded by Eli Lilly; the primary paper and disclosures are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine